Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ASLN
- Price
- -
- Stock movement down
- -0.10 (-14.27%)
- Company name
- Aslan Pharmaceuticals Ltd ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.70M
- Ent value
- 22.25M
- Price/Sales
- 0.14
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -17.52%
- 1 year return
- -97.33%
- 3 year return
- -82.50%
- 5 year return
- -65.85%
- 10 year return
- -
Last updated: 2024-12-16
DIVIDENDS
ASLN does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.14 |
| Price to Book | - |
| EV to Sales | 1.85 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.83M |
| EPS (TTM) | -17.88 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.00M |
| Gross profit (TTM) | 12.00M |
| Operating income (TTM) | -38.41M |
| Net income (TTM) | -38.62M |
| EPS (TTM) | -17.88 |
| EPS (1y forward) | -18.80 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -320.04% |
| Profit margin (TTM) | -321.83% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 18.40M |
| Net receivables | 171.44K |
| Total current assets | 20.58M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 176.39K |
| Total assets | 20.99M |
| Accounts payable | 9.66M |
| Short/Current long term debt | 26.67M |
| Total current liabilities | 19.60M |
| Total liabilities | 38.95M |
| Shareholder's equity | -13.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -156.82% |
| Return on Invested Capital | -477.42% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ASLN | S&P500 | |
| Current price drop from All-time high | -99.85% | -2.16% |
| Highest price drop | -99.85% | -56.47% |
| Date of highest drop | 18 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -78.83% | -11.07% |
| Avg time to new high | 195 days | 12 days |
| Max time to new high | 1538 days | 1805 days |
COMPANY DETAILS
Marketcap
1.70M
Marketcap category
Small-cap
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
Employees
35
Website
Investor relations
-
SEC filings
CEO
Carl Aslan Jason Morton Firth
Country
USA
City
Singapore
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner